Real‐world experience and analyses of the performance of ixekizumab as first‐line biologic agent versus second‐line (or higher) biologic agent in the treatment of chronic plaque psoriasis
Goon PKC, Lim H-Y, Summerfield L, Banfield CC, Sudhoff H, Mallett D (2021)
International Journal of Dermatology 60(8): e319-e320.
Zeitschriftenaufsatz
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Goon, Peter Kin Cho;
Lim, Hai-Yee;
Summerfield, Liz;
Banfield, Cedric Charles;
Sudhoff, HolgerUniBi 
;
Mallett, Dick
;
Mallett, DickErscheinungsjahr
2021
Zeitschriftentitel
International Journal of Dermatology
Band
60
Ausgabe
8
Seite(n)
e319-e320
ISSN
0011-9059
eISSN
1365-4632
Page URI
https://pub.uni-bielefeld.de/record/2953797
Zitieren
Goon PKC, Lim H-Y, Summerfield L, Banfield CC, Sudhoff H, Mallett D. Real‐world experience and analyses of the performance of ixekizumab as first‐line biologic agent versus second‐line (or higher) biologic agent in the treatment of chronic plaque psoriasis. International Journal of Dermatology. 2021;60(8):e319-e320.
Goon, P. K. C., Lim, H. - Y., Summerfield, L., Banfield, C. C., Sudhoff, H., & Mallett, D. (2021). Real‐world experience and analyses of the performance of ixekizumab as first‐line biologic agent versus second‐line (or higher) biologic agent in the treatment of chronic plaque psoriasis. International Journal of Dermatology, 60(8), e319-e320. https://doi.org/10.1111/ijd.15560
Goon, Peter Kin Cho, Lim, Hai-Yee, Summerfield, Liz, Banfield, Cedric Charles, Sudhoff, Holger, and Mallett, Dick. 2021. “Real‐world experience and analyses of the performance of ixekizumab as first‐line biologic agent versus second‐line (or higher) biologic agent in the treatment of chronic plaque psoriasis”. International Journal of Dermatology 60 (8): e319-e320.
Goon, P. K. C., Lim, H. - Y., Summerfield, L., Banfield, C. C., Sudhoff, H., and Mallett, D. (2021). Real‐world experience and analyses of the performance of ixekizumab as first‐line biologic agent versus second‐line (or higher) biologic agent in the treatment of chronic plaque psoriasis. International Journal of Dermatology 60, e319-e320.
Goon, P.K.C., et al., 2021. Real‐world experience and analyses of the performance of ixekizumab as first‐line biologic agent versus second‐line (or higher) biologic agent in the treatment of chronic plaque psoriasis. International Journal of Dermatology, 60(8), p e319-e320.
P.K.C. Goon, et al., “Real‐world experience and analyses of the performance of ixekizumab as first‐line biologic agent versus second‐line (or higher) biologic agent in the treatment of chronic plaque psoriasis”, International Journal of Dermatology, vol. 60, 2021, pp. e319-e320.
Goon, P.K.C., Lim, H.-Y., Summerfield, L., Banfield, C.C., Sudhoff, H., Mallett, D.: Real‐world experience and analyses of the performance of ixekizumab as first‐line biologic agent versus second‐line (or higher) biologic agent in the treatment of chronic plaque psoriasis. International Journal of Dermatology. 60, e319-e320 (2021).
Goon, Peter Kin Cho, Lim, Hai-Yee, Summerfield, Liz, Banfield, Cedric Charles, Sudhoff, Holger, and Mallett, Dick. “Real‐world experience and analyses of the performance of ixekizumab as first‐line biologic agent versus second‐line (or higher) biologic agent in the treatment of chronic plaque psoriasis”. International Journal of Dermatology 60.8 (2021): e319-e320.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Quellen
PMID: 33817799
PubMed | Europe PMC
Suchen in
Google Scholar